3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Other solid neoplasm
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
233
Lung Neoplasms
96
Adenocarcinoma of Lung
39
Colorectal Neoplasms
21
Adenocarcinoma, Bronchiolo-Alveolar
19
Neoplasms
18
Small Cell Lung Carcinoma
13
Non-Squamous Non-Small Cell Lung Cancer
13
Brain Neoplasms
13
Neoplasm Metastasis
10
Ovarian Neoplasms
9
Pleural Effusion, Malignant
8
Breast Neoplasms
8
Stomach Neoplasms
7
Pancreatic Neoplasms
7
Meningeal Carcinomatosis
7
Mesothelioma
6
Melanoma
6
Endometrial Neoplasms
5
Uterine Cervical Neoplasms
4
Triple Negative Breast Neoplasms
4
Rectal Neoplasms
4
Non-squamous Non-small Cell Lung Cancer
4
Carcinoma, Renal Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Recurrence
3
Non-small Cell Lung Cancer Metastatic
3
Mesothelioma, Malignant
3
Esophageal Neoplasms
3
Colonic Neoplasms
3
Interventions
pembrolizumab
3
osimertinib
2
Trastuzumab
2
Magnetic Resonance Spectroscopy
2
Immunoglobulin G
2
ulixertinib
1
tucatinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
seribantumab
1
sapanisertib
1
relatlimab
1
pertuzumab
1
palbociclib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
cobimetinib
1
cemiplimab
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Uncertainty
1
Sunitinib
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Uterine Neoplasms
×
Bevacizumab
×
Thoracic
×
Clear all
NCT05579366
2026-06-03
RAINFOL-01
Genmab
Phase 1/2
Recruiting
884 enrolled